Skip to main content

The Medicines Company Enters Into Definitive Agreement to be Acquired by Novartis AG for $9.7B

Press releases | November 26, 2019

Fried Frank acted as counsel to Goldman Sachs as financial advisor to The Medicines Company in its definitive sale to Novartis AG. Novartis AG will acquire The Medicines Company for US$85 per share in an all-cash transaction, implying a fully diluted equity value of US$9.7 billion. The Medicines Company is a biopharmaceutical company with a focus on addressing cardiovascular disease. Novartis AG is a global healthcare company. The transaction is expected to close in the first quarter of 2020.  

The Fried Frank team was led by corporate partner Philip Richter and included corporate partner Darren A. Littlejohn and corporate associates Brian Klapow and Roy Tannenbaum.


This communication is for general information only. It is not intended, nor should it be relied upon, as legal advice. In some jurisdictions, this may be considered attorney advertising. Please refer to the firm’s data policy page for further information.